{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:53:52Z","timestamp":1793638432759,"version":"4.5.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["1400\\u20131 \\u2013 99\\u201321049"],"award-info":[{"award-number":["1400\\u20131 \\u2013 99\\u201321049"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012021","name":"Iran University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.IUMS.REC.1400.526"],"award-info":[{"award-number":["IR.IUMS.REC.1400.526"]}],"id":[{"id":"10.13039\/100012021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Mycology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.mycmed.2022.101310","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T22:33:56Z","timestamp":1657751636000},"page":"101310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species"],"prefix":"10.1016","volume":"32","author":[{"given":"Hamed","family":"Fakhim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Badali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Dannaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Nasirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fateme","family":"Jahangiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maedeh","family":"Raei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Vaseghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Ahmadikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-7386","authenticated-orcid":false,"given":"Afsane","family":"Vaezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mycmed.2022.101310_bib0001","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.mycmed.2022.101310_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003743","article-title":"Aspergillus fumigatus\u2014What makes the species a ubiquitous human fungal pathogen?","volume":"9","author":"Kwon-Chung","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mycmed.2022.101310_bib0003","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.fbr.2011.01.003","article-title":"Microbial pathogens in the fungal kingdom","volume":"25","author":"Heitman","year":"2011","journal-title":"Fungal Biol Rev"},{"key":"10.1016\/j.mycmed.2022.101310_bib0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.mycmed.2022.101310_bib0005","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkx028","article-title":"Changes in the epidemiological landscape of invasive mould infections and disease","volume":"72","author":"Lass-Fl\u00f6rl","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0006","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0007","doi-asserted-by":"crossref","unstructured":"Vallabhaneni S., Benedict K., Derado G., Mody R.K., editors. Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000\u20132013. Open Forum Infect Dis 2017: Oxford University Press.","DOI":"10.1093\/ofid\/ofw268"},{"key":"10.1016\/j.mycmed.2022.101310_bib0008","first-page":"415","article-title":"Amphotericin B: time for a new\" gold standard\"","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0009","first-page":"561","article-title":"Overview of treatment options for invasive fungal infections","volume":"49","author":"Pound","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0010","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.mycmed.2022.101310_bib0011","first-page":"635","article-title":"Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis","author":"White","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0012","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/myc.12759","article-title":"Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates","volume":"61","author":"Reichert-Lima","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2022.101310_bib0013","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3109\/13693786.2012.684154","article-title":"Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection","volume":"50","author":"Hadrich","year":"2012","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0014","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diagmicrobio.2011.08.006","article-title":"vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"71","author":"Rudramurthy","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0015","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/AAC.01902-12","article-title":"In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi","volume":"57","author":"Gon\u00e7alves","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0016","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1128\/EC.4.3.625-632.2005","article-title":"Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus","volume":"4","author":"Balajee","year":"2005","journal-title":"Eukaryotic Cell"},{"key":"10.1016\/j.mycmed.2022.101310_bib0017","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1128\/JCM.42.10.4805-4808.2004","article-title":"Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection","volume":"42","author":"Azzola","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0018","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1086\/421950","article-title":"Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases","volume":"39","author":"Steinbach","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0019","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1128\/AAC.49.8.3495-3497.2005","article-title":"Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation","volume":"49","author":"Guinea","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0020","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1093\/jac\/dkt232","article-title":"Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis","volume":"68","author":"Barchiesi","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0021","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fmb.10.34","article-title":"In vitro susceptibility testing in Aspergillus species: an update","volume":"5","author":"Lass-Fl\u00f6rl","year":"2010","journal-title":"Future Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0022","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000315360","article-title":"Correlation of proteinase production with amphotericin B resistance in fungi from mycotic keratitis","volume":"44","author":"Nayak","year":"2010","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.mycmed.2022.101310_bib0023","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diagmicrobio.2016.02.009","article-title":"Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program","volume":"85","author":"Castanheira","year":"2013","journal-title":"Diagn Microbiol Infect Dis 2016"},{"key":"10.1016\/j.mycmed.2022.101310_bib0024","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/AAC.00383-13","article-title":"Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)","volume":"57","author":"Alastruey-Izquierdo","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3343\/alm.2015.35.6.602","article-title":"Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea","volume":"35","author":"Heo","year":"2015","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.mycmed.2022.101310_bib0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118997","article-title":"Molecular epidemiology and in-vitro antifungal susceptibility of Aspergillus terreus species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing","volume":"10","author":"Kathuria","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.mycmed.2022.101310_bib0027","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s15010-018-1170-0","article-title":"A nationwide passive surveillance on fungal infections shows a low burden of azole resistance in molds and yeasts in Tyrol","volume":"46","author":"Lass-Fl\u00f6rl","year":"2018","journal-title":"Austria. Infection"},{"key":"10.1016\/j.mycmed.2022.101310_bib0028","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s10096-011-1229-7","article-title":"A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility","volume":"30","author":"Mortensen","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0029","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1128\/AAC.05394-11","article-title":"Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan","volume":"56","author":"Tashiro","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/mmy\/myx067","article-title":"Antifungal susceptibilities to amphotericin B, triazoles and echinocandins of 77 clinical isolates of cryptic Aspergillus species in multicenter surveillance in Korea","volume":"56","author":"Won","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0031","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jiac.2014.01.003","article-title":"Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan","volume":"20","author":"Kikuchi","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0032","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jmii.2018.04.003","article-title":"Antifungal susceptibility of clinical isolates of 25 genetically confirmed Aspergillus species collected from Taiwan and Mainland China","volume":"53","author":"Li","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"10.1016\/j.mycmed.2022.101310_bib0033","doi-asserted-by":"crossref","first-page":"e01927","DOI":"10.1128\/AAC.01927-17","article-title":"Antifungal susceptibility of the Aspergillus viridinutans complex: comparison of two in vitro methods","volume":"62","author":"Lyskova","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.mycmed.2022.101310_bib0034","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/JCM.03088-14","article-title":"Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditions","volume":"53","author":"Guinea","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0035","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3389\/fmicb.2018.01656","article-title":"Aspergillus species and antifungals susceptibility in clinical setting in the north of Portugal: cryptic species and emerging azoles resistance in A. fumigatus","volume":"9","author":"Pinto","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0036","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jac\/dku364","article-title":"Azole, polyene and echinocandin MIC distributions for wild-type, TR34\/L98H and TR46\/Y121F\/T289A Aspergillus fumigatus isolates in the Netherlands","volume":"70","author":"van Ingen","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0037","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1128\/AAC.00304-11","article-title":"Cryptic species and azole resistance in the Aspergillus niger complex","volume":"55","author":"Howard","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186086","article-title":"Diversity of clinical isolates of Aspergillus terreus in antifungal susceptibilities, genotypes and virulence in Galleria mellonella model: comparison between respiratory and ear isolates","volume":"12","author":"Won","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.mycmed.2022.101310_bib0039","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5603\/PiAP.2016.0017","article-title":"Fungal infection of cystic fibrosis patients single center experience","volume":"84","author":"Garczewska","year":"2016","journal-title":"Adv Respir Med"},{"key":"10.1016\/j.mycmed.2022.101310_bib0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1439-0507.2011.02049.x","article-title":"Genetic re-identification and antifungal susceptibility testing of Aspergillus section Nigri strains of the BCCM\/IHEM collection","volume":"55","author":"Hendrickx","year":"2012","journal-title":"Mycoses"},{"issue":"10","key":"10.1016\/j.mycmed.2022.101310_bib0041","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cmi.2017.04.012","article-title":"A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study","volume":"23","author":"Risslegger","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2022.101310_bib0042","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/myc.12716","article-title":"In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex","volume":"61","author":"Vaezi","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2022.101310_bib0043","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ijantimicag.2012.01.013","article-title":"In vitro activities of amphotericin B and AmBisome against Aspergillus isolates recovered from Italian patients treated for haematological malignancies","volume":"39","author":"Colozza","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mycmed.2022.101310_bib0044","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1128\/AAC.00045-15","article-title":"In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of Aspergillus terreus sensu stricto","volume":"59","author":"Fern\u00e1ndez","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0045","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1128\/AAC.01569-10","article-title":"In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species","volume":"55","author":"Fiori","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0046","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.mycmed.2016.01.002","article-title":"In vitro activities of five antifungal agents against 199 clinical and environmental isolates of Aspergillus flavus, an opportunistic fungal pathogen","volume":"26","author":"Khodavaisy","year":"2016","journal-title":"J Mycol Med"},{"key":"10.1016\/j.mycmed.2022.101310_bib0047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11046-015-9968-0","article-title":"In vitro activities of five antifungal drugs against opportunistic agents of Aspergillus Nigri complex","volume":"181","author":"Badali","year":"2016","journal-title":"Mycopathologia"},{"key":"10.1016\/j.mycmed.2022.101310_bib0048","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.00570-11","article-title":"In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods","volume":"55","author":"Pfaller","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0049","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijantimicag.2010.06.003","article-title":"In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan","volume":"36","author":"Yamazaki","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mycmed.2022.101310_bib0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/13693780902803040","article-title":"In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus","volume":"48","author":"Alastruey-Izquierdo","year":"2010","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0051","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/myc.12299","article-title":"In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012","volume":"58","author":"Pfaller","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2022.101310_bib0052","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bjid.2017.10.005","article-title":"In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil","volume":"22","author":"Denardi","year":"2018","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0053","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1111\/j.1439-0507.2010.01996.x","article-title":"In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs","volume":"54","author":"Shivaprakash","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2022.101310_bib0054","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1128\/AAC.01141-13","article-title":"In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole","volume":"57","author":"Gregson","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-3-19","article-title":"In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia","volume":"3","author":"Gheith","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/j.mycmed.2022.101310_bib0056","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/605308","article-title":"Microscopic evaluation, molecular identification, antifungal susceptibility, and clinical outcomes in Fusarium, Aspergillus and, Dematiaceous keratitis","author":"Gajjar","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.mycmed.2022.101310_bib0057","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/0301-4738.83614","article-title":"Molecular characterization of drug-resistant and drug-sensitive Aspergillus isolates causing infectious keratitis","volume":"59","author":"Nayak","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-13-126","article-title":"Molecular identification and antifungal susceptibility profile of Aspergillus flavus isolates recovered from clinical specimens in Kuwait","volume":"13","author":"Al-Wathiqi","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0059","doi-asserted-by":"crossref","first-page":"e01792","DOI":"10.1128\/AAC.01792-16","article-title":"Multicenter study of method-dependent epidemiological cutoff values for detection of resistance in Candida spp. and Aspergillus spp. to amphotericin B and echinocandins for the Etest agar diffusion method","volume":"61","author":"Espinel-Ingroff","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0060","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1128\/AAC.01491-10","article-title":"Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece","volume":"55","author":"Arabatzis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0061","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jiac.2015.01.005","article-title":"Secondary metabolite profiles and antifungal drug susceptibility of Aspergillus fumigatus and closely related species, Aspergillus lentulus, Aspergillus udagawae, and Aspergillus viridinutans","volume":"21","author":"Tamiya","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0062","doi-asserted-by":"crossref","first-page":"e02315","DOI":"10.1128\/AAC.02315-17","article-title":"Species identification and in vitro antifungal susceptibility of Aspergillus terreus species complex clinical isolates from a french multicenter study","volume":"62","author":"Imbert","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0063","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3109\/13693786.2011.583943","article-title":"Lass-Fl\u00f6rl C. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey","volume":"49","author":"Rambach","year":"2011","journal-title":"Med Mycol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0064","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ijantimicag.2009.12.007","article-title":"Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy","volume":"35","author":"Amorim","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.mycmed.2022.101310_bib0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11046-015-9969-z","article-title":"Time-kill kinetics and in vitro antifungal susceptibility of non-fumigatus Aspergillus species isolated from patients with ocular mycoses","volume":"181","author":"\u00d6z","year":"2016","journal-title":"Mycopathologia"},{"key":"10.1016\/j.mycmed.2022.101310_bib0066","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11046-016-0018-3","article-title":"Virulence attributes and antifungal susceptibility profile of opportunistic fungi isolated from ophthalmic infections","volume":"181","author":"Sav","year":"2016","journal-title":"Mycopathologia"},{"key":"10.1016\/j.mycmed.2022.101310_bib0067","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1111\/j.1469-0691.2011.03714.x","article-title":"Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B","volume":"18","author":"Escribano","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.mycmed.2022.101310_bib0068","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/jof3020027","article-title":"MIC distributions and evaluation of fungicidal activity for amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin and 20 species of pathogenic filamentous fungi determined using the CLSI broth microdilution method","volume":"3","author":"Borman","year":"2017","journal-title":"J Fungi"},{"key":"10.1016\/j.mycmed.2022.101310_bib0069","doi-asserted-by":"crossref","first-page":"e02583","DOI":"10.1128\/AAC.02583-16","article-title":"Drug sensitivity and resistance mechanism in Aspergillus section Nigri strains from Japan","volume":"61","author":"Hashimoto","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0070","doi-asserted-by":"crossref","first-page":"e00780","DOI":"10.1128\/JCM.00780-18","article-title":"Comparison of the Sensititre YeastOne and CLSI M38-A2 microdilution methods in determining the activity of amphotericin B, itraconazole, voriconazole, and posaconazole against Aspergillus species","volume":"56","author":"Wang","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0071","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1128\/AAC.00686-11","article-title":"Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"55","author":"Espinel-Ingroff","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0072","doi-asserted-by":"crossref","first-page":"e02264","DOI":"10.1128\/AAC.02264-17","article-title":"Emergence of azole-resistant Aspergillus fumigatus from immunocompromised hosts in India","volume":"62","author":"Dabas","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0073","doi-asserted-by":"crossref","first-page":"e00358","DOI":"10.1128\/AAC.00358-18","article-title":"Molecular identification and susceptibility testing of molds isolated in a prospective surveillance of triazole resistance in Spain (FILPOP2 Study)","volume":"62","author":"Alastruey-Izquierdo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0074","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.3389\/fmicb.2018.02234","article-title":"Surveillance for azole-resistant Aspergillus fumigatus in a centralized diagnostic mycology service, London, United Kingdom, 1998\u20132017","volume":"9","author":"Abdolrasouli","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0075","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/IDR.S170952","article-title":"Widespread amphotericin B-resistant strains of Aspergillus fumigatus in Hamilton","volume":"11","author":"Ashu","year":"2018","journal-title":"Canada. Infect Drug Resist"},{"key":"10.1016\/j.mycmed.2022.101310_bib0076","doi-asserted-by":"crossref","first-page":"e00244","DOI":"10.1128\/AAC.00244-18","article-title":"Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis","volume":"62","author":"Ghannoum","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0077","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/jof5020041","article-title":"Antifungal resistance in clinical isolates of Aspergillus spp.: when local epidemiology breaks the norm","volume":"5","author":"Romero","year":"2019","journal-title":"J Fungi"},{"key":"10.1016\/j.mycmed.2022.101310_bib0078","doi-asserted-by":"crossref","first-page":"e02023","DOI":"10.1128\/JCM.02023-18","article-title":"Epidemiology and antifungal susceptibility profile of Aspergillus species: comparison between environmental and clinical isolates from patients with hematologic malignancies","volume":"57","author":"Cho","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0079","doi-asserted-by":"crossref","first-page":"e00840","DOI":"10.1128\/AAC.00840-19","article-title":"In vitro activity of APX001A (manogepix) and comparator agents against 1,706 fungal isolates collected during an international surveillance program in 2017","volume":"63","author":"Pfaller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3389\/fmicb.2019.01677","article-title":"The emergence of rare clinical Aspergillus species in Qatar: molecular characterization and antifungal susceptibility profiles","volume":"10","author":"Salah","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0081","first-page":"510","article-title":"The potency of luliconazole against clinical and environmental Aspergillus nigri complex","volume":"11","author":"Hivary","year":"2019","journal-title":"Iran J Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0082","doi-asserted-by":"crossref","first-page":"e00865","DOI":"10.1128\/AAC.00865-19","article-title":"Alastruey-Izquierdo A. Molecular identification, antifungal susceptibility testing, and mechanisms of azole resistance in Aspergillus species received within a surveillance program on antifungal resistance in Spain","volume":"63","author":"Rivero-Menendez","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0083","doi-asserted-by":"crossref","first-page":"e02689","DOI":"10.1128\/AAC.02689-18","article-title":"ASP2397 is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0084","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6395840","article-title":"Fungal keratitis: epidemiology, rapid detection, and antifungal susceptibilities of Fusarium and Aspergillus isolates from corneal scrapings","volume":"2019","author":"Manikandan","year":"2019","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.mycmed.2022.101310_bib0085","doi-asserted-by":"crossref","first-page":"e00073","DOI":"10.1128\/AAC.00073-19","article-title":"EUCAST susceptibility testing of isavuconazole: MIC data for contemporary clinical mold and yeast isolates","volume":"63","author":"J\u00f8rgensen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0086","first-page":"4865","article-title":"MALDI\u2011TOF MS for the rapid identification and drug susceptibility testing of filamentous fungi","volume":"18","author":"Peng","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.mycmed.2022.101310_bib0087","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2147\/IDR.S259162","article-title":"A 9-Year Experience of Aspergillus Infections from Isfahan","volume":"13","author":"Chadeganipour","year":"2020","journal-title":"Iran. Infect. Drug Resist"},{"key":"10.1016\/j.mycmed.2022.101310_bib0088","doi-asserted-by":"crossref","first-page":"e00099","DOI":"10.1128\/AAC.00099-20","article-title":"Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018)","volume":"64","author":"Pfaller","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0089","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/12298093.2020.1744955","article-title":"Antifungal susceptibility tests and the cyp51 mutant strains among clinical Aspergillus fumigatus isolates from Korean multicenters","volume":"48","author":"Won","year":"2020","journal-title":"Mycobiology"},{"key":"10.1016\/j.mycmed.2022.101310_bib0090","first-page":"170","article-title":"The high efficacy of luliconazole against environmental and otomycosis Aspergillus flavus strains","volume":"12","author":"Moslem","year":"2020","journal-title":"Iran J Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0091","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/myc.12717","article-title":"Use of cell surface protein typing for genotyping of azole-resistant and-susceptible Aspergillus fumigatus isolates in Iran","volume":"61","author":"Falahatinejad","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.mycmed.2022.101310_bib0092","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/IDR.S124918","article-title":"Antifungal resistance: current trends and future strategies to combat","volume":"10","author":"Wiederhold","year":"2017","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.mycmed.2022.101310_bib0093","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jac\/42.4.497","article-title":"In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis","volume":"42","author":"Lass-Fl\u00f6rl","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0094","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1128\/AAC.47.10.3085-3088.2003","article-title":"In vitro activities of three licensed antifungal agents against Spanish clinical isolates of Aspergillus spp","volume":"47","author":"Gomez-Lopez","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0095","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1067\/mjd.2002.120627","article-title":"Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent","volume":"46","author":"Koss","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0096","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1128\/AAC.06015-11","article-title":"Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity","volume":"56","author":"Clemons","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0097","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.actbio.2016.09.036","article-title":"Biodegradable functional polycarbonate micelles for controlled release of amphotericin B","volume":"46","author":"Wang","year":"2016","journal-title":"Acta Biomater"},{"key":"10.1016\/j.mycmed.2022.101310_bib0098","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2015.08.003","article-title":"Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections","volume":"494","author":"Moreno-Rodr\u00edguez","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.mycmed.2022.101310_bib0099","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.00870-07","article-title":"Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products","volume":"52","author":"Olson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0100","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1128\/AAC.45.5.1456-1462.2001","article-title":"Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo","volume":"45","author":"Mosquera","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0101","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/lt.24032","article-title":"Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases","volume":"21","author":"Barchiesi","year":"2015","journal-title":"Liver Transplant"},{"key":"10.1016\/j.mycmed.2022.101310_bib0102","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1128\/AAC.02484-12","article-title":"Single-dose pharmacodynamics of amphotericin B against Aspergillus species in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Al-Saigh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0103","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00233-15","article-title":"Nationwide surveillance of azole resistance in Aspergillus diseases","volume":"59","author":"Vermeulen","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0104","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1128\/JCM.00925-15","article-title":"Comparing Etest and broth microdilution for antifungal susceptibility testing of the most-relevant pathogenic molds","volume":"53","author":"Lamoth","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.mycmed.2022.101310_bib0105","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1128\/AAC.00692-10","article-title":"Environmental study of azole-resistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain","volume":"54","author":"Mortensen","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0106","doi-asserted-by":"crossref","first-page":"e00489","DOI":"10.1128\/AAC.00489-18","article-title":"Efficacy, biodistribution, and nephrotoxicity of experimental amphotericin B-deoxycholate formulations for pulmonary aspergillosis","volume":"62","author":"L\u00f3pez-S\u00e1nchez","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mycmed.2022.101310_bib0107","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations","volume":"9","author":"Natesan","year":"2016","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.mycmed.2022.101310_bib0108","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2147\/DDDT.S145545","article-title":"Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy","volume":"12","author":"Jenks","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.mycmed.2022.101310_bib0109","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2018.03.003","article-title":"In vitro combination of voriconazole with micafungin against azole-resistant clinical isolates of Aspergillus fumigatus from different geographical regions","volume":"91","author":"Fakhim","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.mycmed.2022.101310_bib0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Stat Soc: Series A (Stat Soc)"}],"container-title":["Journal of Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523322000671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1156523322000671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:17:07Z","timestamp":1777609027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1156523322000671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":110,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1156523322000671"],"URL":"https:\/\/doi.org\/10.1016\/j.mycmed.2022.101310","relation":{},"ISSN":["1156-5233"],"issn-type":[{"value":"1156-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in the Prevalence of Amphotericin B-Resistance (AmBR) among Clinical Isolates of Aspergillus Species","name":"articletitle","label":"Article Title"},{"value":"Journal of Medical Mycology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mycmed.2022.101310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 SFMM. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101310"}}